JP2020533948A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533948A5
JP2020533948A5 JP2019559017A JP2019559017A JP2020533948A5 JP 2020533948 A5 JP2020533948 A5 JP 2020533948A5 JP 2019559017 A JP2019559017 A JP 2019559017A JP 2019559017 A JP2019559017 A JP 2019559017A JP 2020533948 A5 JP2020533948 A5 JP 2020533948A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019559017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533948A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/045068 external-priority patent/WO2019028292A1/en
Publication of JP2020533948A publication Critical patent/JP2020533948A/ja
Publication of JP2020533948A5 publication Critical patent/JP2020533948A5/ja
Priority to JP2022186859A priority Critical patent/JP7554247B2/ja
Priority to JP2024091312A priority patent/JP2024147536A/ja
Pending legal-status Critical Current

Links

JP2019559017A 2017-08-03 2018-08-02 抗trem2抗体及びその使用方法 Pending JP2020533948A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022186859A JP7554247B2 (ja) 2017-08-03 2022-11-22 抗trem2抗体及びその使用方法
JP2024091312A JP2024147536A (ja) 2017-08-03 2024-06-05 抗trem2抗体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762541019P 2017-08-03 2017-08-03
US62/541,019 2017-08-03
US201862636095P 2018-02-27 2018-02-27
US62/636,095 2018-02-27
PCT/US2018/045068 WO2019028292A1 (en) 2017-08-03 2018-08-02 ANTI-TREM2 ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186859A Division JP7554247B2 (ja) 2017-08-03 2022-11-22 抗trem2抗体及びその使用方法

Publications (2)

Publication Number Publication Date
JP2020533948A JP2020533948A (ja) 2020-11-26
JP2020533948A5 true JP2020533948A5 (https=) 2021-09-09

Family

ID=63364160

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019559017A Pending JP2020533948A (ja) 2017-08-03 2018-08-02 抗trem2抗体及びその使用方法
JP2022186859A Active JP7554247B2 (ja) 2017-08-03 2022-11-22 抗trem2抗体及びその使用方法
JP2024091312A Pending JP2024147536A (ja) 2017-08-03 2024-06-05 抗trem2抗体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022186859A Active JP7554247B2 (ja) 2017-08-03 2022-11-22 抗trem2抗体及びその使用方法
JP2024091312A Pending JP2024147536A (ja) 2017-08-03 2024-06-05 抗trem2抗体及びその使用方法

Country Status (34)

Country Link
US (3) US10676525B2 (https=)
EP (2) EP4248996A3 (https=)
JP (3) JP2020533948A (https=)
KR (2) KR102769231B1 (https=)
CN (3) CN119192376A (https=)
AU (1) AU2018311055B2 (https=)
BR (1) BR112019022752A2 (https=)
CA (1) CA3061755A1 (https=)
CL (2) CL2019003093A1 (https=)
CO (1) CO2019012210A2 (https=)
CR (3) CR20230170A (https=)
DK (1) DK3601358T5 (https=)
EC (1) ECSP19078429A (https=)
ES (1) ES2952982T3 (https=)
FI (1) FI3601358T3 (https=)
HR (1) HRP20230675T1 (https=)
HU (1) HUE062436T2 (https=)
IL (2) IL315241A (https=)
LT (1) LT3601358T (https=)
MD (1) MD3601358T2 (https=)
MX (2) MX2019012868A (https=)
MY (1) MY201526A (https=)
NZ (1) NZ758301A (https=)
PE (1) PE20200148A1 (https=)
PH (1) PH12019502459A1 (https=)
PL (1) PL3601358T3 (https=)
PT (1) PT3601358T (https=)
RS (1) RS64419B1 (https=)
SI (1) SI3601358T1 (https=)
SM (1) SMT202300281T1 (https=)
TW (3) TWI868807B (https=)
UA (1) UA129513C2 (https=)
WO (1) WO2019028292A1 (https=)
ZA (2) ZA201906730B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3177322A4 (en) 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
CA2961950A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
BR112019022752A2 (pt) 2017-08-03 2020-05-19 Alector Llc anticorpos anti-trem2 e métodos de uso dos mesmos
WO2019118513A1 (en) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CN113302206A (zh) 2018-11-26 2021-08-24 戴纳立制药公司 治疗脂质代谢失调的方法
PH12021552002A1 (en) * 2019-02-20 2022-09-19 Denali Therapeutics Inc Anti-trem2 antibodies and methods of use thereof
JP7368624B2 (ja) 2019-11-22 2023-10-24 イーライ リリー アンド カンパニー Trem2抗体およびそれらの使用
MX2022006073A (es) * 2019-12-05 2022-08-04 Alector Llc Metodos para utilizar anticuerpos anti-trem2.
PE20221465A1 (es) 2020-01-13 2022-09-21 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos
TWI890727B (zh) 2020-01-13 2025-07-21 美商戴納立製藥公司 抗trem2 抗體及其使用方法
CA3167851A1 (en) * 2020-02-24 2021-09-02 Francesca CIGNARELLA Methods of use of anti-trem2 antibodies
CN115667308A (zh) * 2020-04-03 2023-01-31 艾利妥 抗trem2抗体的使用方法
AU2022273303A1 (en) 2021-05-14 2023-11-02 Genentech, Inc. Agonists of trem2
JP2025503437A (ja) 2021-12-17 2025-02-04 デナリ セラピューティクス インコーポレイテッド ポリペプチド操作、ライブラリー、ならびに操作されたcd98重鎖及びトランスフェリン受容体結合ポリペプチド
EP4482523A1 (en) 2022-02-23 2025-01-01 Alector LLC Methods of use of anti-trem2 antibodies
EP4499693A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
EP4499695A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
JP2025529287A (ja) 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのtrem-2アゴニスト
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024253420A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간 항체 및 이의 용도
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025166058A1 (en) * 2024-01-31 2025-08-07 Alector Llc Multi-specific proteins that bind to trem2 and transferrin receptor and uses therefor
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
CN118546252A (zh) * 2024-04-02 2024-08-27 上海宏成药业有限公司 抗trem2抗体及其用途
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2331386A1 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2462883A1 (en) 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
EP1508340A4 (en) 2002-05-24 2009-07-01 Takeda Pharmaceutical MEANS FOR IMPROVING INSULIN RESISTANCE
JP2004073182A (ja) 2002-05-24 2004-03-11 Takeda Chem Ind Ltd インスリン抵抗性改善剤
US20040119010A1 (en) 2002-11-01 2004-06-24 The Regents Of The University Of Colorado Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
CA2503390A1 (en) 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4902961B2 (ja) 2002-12-23 2012-03-21 シェーリング コーポレイション 哺乳動物サイトカインの用途;関連試薬
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8101345B1 (en) 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
DE202006007499U1 (de) 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US8093360B2 (en) * 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
US7673853B2 (en) 2006-10-12 2010-03-09 Cordell Eldred Ebeling Fencing section with adjustable fencing members
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
US20080247955A1 (en) * 2007-01-16 2008-10-09 Jun Kuai Inflammation treatment, detection and monitoring via TREM-1
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP2010540660A (ja) 2007-10-05 2010-12-24 ユニバーシティ オブ メリーランド,ボルチモア 哺乳類内の赤血球生成を刺激する新規の組成物および方法
KR100960684B1 (ko) 2008-02-22 2010-05-31 전남대학교산학협력단 Ga733-2 발현 억제제로서의 trem-2 유전자, 및 이를포함하는 형질전환 동물 및 이의 사용방법
EP2186928A1 (en) 2008-11-14 2010-05-19 Enthone, Inc. Method for the post-treatment of metal layers
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US8513185B2 (en) 2009-10-13 2013-08-20 Alexander B. Sigalov Inhibition of TREM receptor signaling with peptide variants
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究(慕尼黑)有限責任公司 跨物種專一性之PSMAxCD3雙專一性單鏈抗體
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
TWI559929B (en) * 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
CA2825821A1 (en) 2013-08-28 2015-02-28 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of alzheimer's disease and multiple sclerosis
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
WO2016004389A2 (en) 2014-07-03 2016-01-07 Abbvie Inc. Monovalent binding proteins
EP3177322A4 (en) 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CA2961950A1 (en) * 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016064895A1 (en) * 2014-10-20 2016-04-28 The Brigham And Women's Hospital, Inc. Targeting apolipoprotein e (apoe) in neurologic disease
AU2016246695A1 (en) 2015-04-07 2017-10-26 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
WO2016187339A1 (en) 2015-05-18 2016-11-24 Synaptec Development Llc GALANTAMINE CLEARANCE OF AMYLOIDß
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
AU2016334051B2 (en) * 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
KR102415925B1 (ko) * 2016-01-11 2022-07-04 삼성디스플레이 주식회사 표시장치
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
EP3487886A2 (en) 2016-07-22 2019-05-29 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Trem2 cleavage modulators and uses thereof
CN109843916B (zh) 2016-08-12 2023-10-31 詹森生物科技公司 具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法
US20190367623A1 (en) 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
WO2018140831A2 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US20190008812A1 (en) 2017-07-07 2019-01-10 Washington University Methods for treating microglial dysfunction
KR20200032722A (ko) 2017-07-27 2020-03-26 노파르티스 아게 부분절단효소 내성 trem2 변이체
KR102733407B1 (ko) 2017-08-03 2024-11-21 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
BR112019022752A2 (pt) 2017-08-03 2020-05-19 Alector Llc anticorpos anti-trem2 e métodos de uso dos mesmos
WO2019055841A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
KR102709597B1 (ko) 2017-10-03 2024-09-26 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
WO2019079529A1 (en) 2017-10-17 2019-04-25 The Translational Genomics Research Institute TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS
WO2019118513A1 (en) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
CA3091047A1 (en) 2018-02-14 2019-08-22 Yale University Compositions for modulation of a trem or treml protein and methods of use
CN115667308A (zh) * 2020-04-03 2023-01-31 艾利妥 抗trem2抗体的使用方法
AU2022273303A1 (en) * 2021-05-14 2023-11-02 Genentech, Inc. Agonists of trem2

Similar Documents

Publication Publication Date Title
JP2020533948A5 (https=)
US20240018235A1 (en) Cd3 binding antibodies
JP7575100B2 (ja) 免疫細胞活性化のための二重特異性抗体
US20230322920A1 (en) Multi-specific antibodies and methods of making and using thereof
JP7323513B2 (ja) 抗4-1bb抗体とその作製及び使用方法
CN114395048B (zh) Cd3结合抗体
JP2020532947A5 (https=)
HRP20230675T1 (hr) Anti-trem2 protutijela i postupci njihove uporabe
CA3102036A1 (en) Cytokine fusion proteins and uses thereof
JP2017523814A5 (https=)
JP7263256B6 (ja) Pd-l1抗体医薬組成物およびその使用
CA3086653A1 (en) Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa)
CA3021372A1 (en) Anti-pd-1 antibodies, a method of production and a method of use thereof
JP2021529520A5 (https=)
CA2892623A1 (en) Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
US20230114801A1 (en) MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF
JP2021534797A5 (https=)
TW202233674A (zh) 用於調節δγ鏈介導之免疫的組成物及方法
JP2021531027A5 (https=)
US20250206820A1 (en) Ilt3 and cd3 binding agents and methods of use thereof
JP7657591B2 (ja) 二重特異性抗原結合コンストラクト
JP2021513328A5 (https=)
JP2024503297A (ja) 多重特異性抗原結合タンパク質
US20250043001A1 (en) Anti-cd28 compositions
CN121311507A (zh) 抗cd28 x抗trop2抗体